Department of Rheumatology & Immunology, The First Affiliated Hospital of Anhui Medical University, Hefei, China.
Clin Rheumatol. 2017 Nov;36(11):2581-2587. doi: 10.1007/s10067-017-3807-2. Epub 2017 Sep 5.
Osteoporosis (OP) is one of the signs of bone damage in rheumatoid arthritis (RA). The 14-3-3η protein is an inflammatory protein, which has been reported to be associated with rheumatoid arthritis (RA). This is to determine the serum levels of 14-3-3η protein, evaluate its diagnostic value in early RA, and clear out its significance in RA with secondary osteoporosis. Two hundred fifty-nine RA patients and 80 age and sex-matched healthy controls were included. Assays of serum 14-3-3η protein were done for all participants by enzyme-linked immunosorbent assay (ELISA). Dual-energy X-ray absorptiometry (DEXA) was used to measure bone mineral density (BMD). Serum 14-3-3η protein level was significantly high in RA (2.49/4.72), compared with controls (P < 0.0001). Positive rate of 14-3-3η protein in RA was 97.3%, which was higher than that in controls (χ = 276.641, P < 0.0001). Serum 14-3-3η protein level in early RA was significantly higher than that in established RA (3.91/4.82 vs 2.01/3.29, Z = 2.624, P < 0.05). The positive rate among three groups (normal control, early RA group, established RA group) differed from each other (χ = 131.396, P < 0.0001). Results of ROC curve indicated the cutoff point of 14-3-3η protein for diagnosis of early RA was 0.879 ng/ml (P < 0.0001). Linear correlation analysis found that serum 14-3-3η protein positively correlated with VAS and HAQ (P < 0.0001), negatively correlated with BMD at lumbar spine and femur in RA (P < 0.0001). Serum 14-3-3η protein among groups of bone mass normal (2.73/3.79), osteopenia (3.15/4.86), and osteoporosis (6.34/6.42) was different in early RA patients (χ = 7.974, P < 0.05). Serum 14-3-3η protein levels increase significantly in patients with RA (especially in early RA). There are close relationships between serum 14-3-3η protein and clinical symptoms and osteoporosis in patients with RA.
骨质疏松症 (OP) 是类风湿关节炎 (RA) 骨骼损害的标志之一。14-3-3η 蛋白是一种炎症蛋白，据报道与类风湿关节炎 (RA) 有关。本研究旨在测定血清 14-3-3η 蛋白水平，评估其在早期 RA 中的诊断价值，并明确其在继发性骨质疏松症中的意义。纳入 259 例 RA 患者和 80 名年龄和性别匹配的健康对照者。所有参与者均采用酶联免疫吸附试验 (ELISA) 检测血清 14-3-3η 蛋白。双能 X 线吸收法 (DEXA) 用于测量骨密度 (BMD)。RA 患者血清 14-3-3η 蛋白水平明显高于对照组 (2.49/4.72，P<0.0001)。RA 患者 14-3-3η 蛋白的阳性率为 97.3%，高于对照组 (χ2=276.641，P<0.0001)。早期 RA 患者血清 14-3-3η 蛋白水平明显高于已确诊的 RA 患者 (3.91/4.82 比 2.01/3.29，Z=2.624，P<0.05)。三组 (正常对照组、早期 RA 组、已确诊的 RA 组) 之间的阳性率存在差异 (χ2=131.396，P<0.0001)。ROC 曲线结果表明，血清 14-3-3η 蛋白诊断早期 RA 的截断点为 0.879ng/ml (P<0.0001)。线性相关分析发现，血清 14-3-3η 蛋白与 VAS 和 HAQ 呈正相关 (P<0.0001)，与 RA 患者腰椎和股骨的 BMD 呈负相关 (P<0.0001)。早期 RA 患者骨量正常 (2.73/3.79)、骨量减少 (3.15/4.86) 和骨质疏松 (6.34/6.42) 组之间的血清 14-3-3η 蛋白水平存在差异 (χ2=7.974，P<0.05)。RA 患者血清 14-3-3η 蛋白水平显著升高 (尤其是早期 RA 患者)。血清 14-3-3η 蛋白与 RA 患者的临床症状和骨质疏松密切相关。
